ReviewClinical journal of oncology nursing2025
Using Electronic Patient-Reported Outcome Measures for Patients With Metastatic Renal Cell Carcinoma: A Narrative Review.
Review in Clinical journal of oncology nursing, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe variety of therapeutic associations in first-line treatment of advanced and metastatic renal cell cancer (mRCC) illustrates the complexity of toxicity management that can affect patients' health-related quality of life (HRQOL). Electronic monitoring applications have become part of the daily practice of providers in following up with people with cancer.
objectivesThis article offers perspectives for electronic patient-reported outcome measures (ePROMs) in clinical practice to enhance symptom management and HRQOL for patients with mRCC.
methodsA narrative review combines the results of searches conducted on MEDLINE®, Embase®, and Cochrane Library for articles that identify therapeutic combinations used in treating mRCC, extract HRQOL data, and evaluate the benefits of ePROMs.
findingsePROMs can be adapted to the toxicity and symptom specificities encountered in patients with mRCC undergoing front-line treatment. Combined with multidimensional HRQOL indicators, these tools can improve symptom management and provide early support adapted to the patient's needs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.